| Vol. 13.13 – 15 April, 2021 |
| |
|
|
| The therapeutic effects of umbilical cord MSC-derived extracellular vesicleson pulmonay fibrosis were evaluated using bleomycin-induced mouse models. [Stem Cell Research & Therapy] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists generated an induced pluripotent stem cell line GZHMCi004-A derived from umbilical cord blood mononuclear cells of a fetus with heterozygous G380R mutation in FGFR3 gene. [Stem Cell Research] |
|
|
|
| Researchers studied the underlying mechanism of extracellular vesicle‐derived microRNA‐18 in preeclampsia. [Journal of Cellular and Molecular Medicine] |
|
|
|
| Expression of Angiotensin-Converting Enzyme 2 (ACE2) and transmembrane Serine Protease 2 (TMPRSS2) was analyzed in 24 lots of human umbilical cord-MSCs derived from Wharton’s jelly via quantitative PCR, Western Blot, immunofluorescence and flow cytometry using 24 different donors. [Journal of Translational Medicine] |
|
|
|
| Researchers concluded that, after pre-term birth onset, a shift from immunoregulation towards inflammation takes place in cord blood cells that were reportedly representative of the fetal compartment. [Journal of Reproductive Immunology] |
|
|
|
| Untargeted nuclear magnetic resonance metabolomics was applied in 84 umbilical cord blood and maternal blood samples obtained from 48 intrauterine growth restriction and 36 appropriate for gestational age deliveries. [Scientific Reports] |
|
|
|
| Investigators examined the epigenetic effects induced by in utero chlordecone exposure on human male cord blood as well as in blood-derived Ke-37 cell line. [Life Science Alliance] |
|
|
|
|
| Scientists summarize the current state of MSC-based cell therapy, focusing on the systemic safety and biodistribution of MSCs. [Journal of Biomedical Science] |
|
|
|
|
| Sentien Biotechnologies, Inc. announced it has completed enrollment of the first cohort in its Phase I/II study of SBI-101 for the treatment of severe COVID-19. SBI-101 is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome and acute kidney injur requiring renal replacement therapy. [Sentien Biotechnologies, Inc.] |
|
|
|
| Celularity, Inc. announced FDA has granted Orphan Drug Designation to the company’s non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, for the treatment of patients with malignant gliomas. [Celularity, Inc.] |
|
|
|
| Therapeutic Solutions International, Inc., announced filing of a patent with new data covering a cord blood based intranasal product demonstrated to reduce adverse mental effects associated with opioid addiction. [Therapeutic Solutions International, Inc. (PR Newswire)] |
|
|
|
|
| September 22 – 24, 2021 Virtual |
|
|
|
|
|
| Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| University of Chicago – Chicago, Illinois, United States |
|
|
|
| American Association for Cancer Research – Boston, Massachusetts, United States |
|
|
|
| Moores Cancer Center – La Jolla, California, United States |
|
|
|
| University of Washington – Seattle, Washington, United States |
|
|
|
|